Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $287M (up 362.0% year over year) with net income of −$114M.
Q3 2025 key financials · XBRL
- Revenue
- $287M
- +362.0% YoY · +35.0% QoQ
- Net income
- −$114M
- −6.8% YoY · −170.1% QoQ
- Operating margin
- -39.7%
- EPS (diluted)
- −$5.10
- −5.4% YoY · −168.4% QoQ
Source: XBRL data from the MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q3 2025 10-Q on SEC EDGAR. USD.
MADRIGAL PHARMACEUTICALS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $287.3M Q3 2025 vs $62.2M Q3 2024, up 362% due to increased Rezdiffra demand
- Operating loss stable: $(114.0)M Q3 2025 vs $(116.3)M Q3 2024, 2% improvement
- Best segment: Rezdiffra sales, $287.3M Q3 2025, cost of sales $18.1M (6.3% margin); worst: R&D expenses $174.0M, up 153% YoY
- Cash, cash equivalents, restricted cash $1,114.7M Sept 2025 vs $931.3M Dec 2024; net cash used in operating activities $56.1M YTD 2025 vs $351.1M YTD 2024
- Management highlights continued losses, sufficient cash for >1 year, notes risks from clinical expenses, commercialization, $120M upfront CSPC license payment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MADRIGAL PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.